ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 9.66% |
2IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 5.28% |
3BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 4.62% |
4BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 3.21% |
5MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 2.99% |
6BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 2.96% |
7XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 2.74% |
8BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 2.67% |
9SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 2.43% |
10TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 2.37% |
11ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 2.35% |
12ABSI | ABSCI CORP | Healthcare | $1.57B | 2.35% |
13NVAX | NOVAVAX INC | Healthcare | $1.45B | 2.16% |
14OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 2.07% |
15CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 1.93% |
16INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 1.92% |
17ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 1.64% |
18AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 1.61% |
19VSTM | VERASTEM INC | Healthcare | $1.06B | 1.59% |
20ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $881M | 1.32% |
21SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 1.28% |
22MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 1.26% |
23GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 1.19% |
24ALMS | ALUMIS INC | Healthcare | $793M | 1.19% |
25SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 1.17% |
26AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 1.11% |
27CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 1.08% |
28QUIT | ACHIEVE LIFE SCIENCES INC | Healthcare | $692M | 1.04% |
29KURA | KURA ONCOLOGY INC | Healthcare | $683M | 1.02% |
30BCAX | BICARA THERAPEUTICS INC | Healthcare | $671M | 1.00% |
31DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.99% |
32CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.99% |
33OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $659M | 0.99% |
34CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.96% |
35CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $595M | 0.89% |
36IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.86% |
37AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 0.85% |
38ETRA | ELECTRA THERAPEUTICS INC | Healthcare | $557M | 0.83% |
39SENS | SENSEONICS HOLDINGS INC | Healthcare | $550M | 0.82% |
40MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.81% |
41RGNX | REGENXBIO INC | Healthcare | $531M | 0.79% |
42TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.78% |
43SRTA | STRATA CRITICAL MEDICAL INC | Healthcare | $515M | 0.77% |
44PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.76% |
45DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.75% |
46OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 0.72% |
47EOLS | EVOLUS INC | Healthcare | $475M | 0.71% |
48ARVN | ARVINAS INC | Healthcare | $450M | 0.67% |
49AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.67% |
50PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.63% |
51PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.62% |
52MASS | 908 DEVICES INC | Healthcare | $407M | 0.61% |
53CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $384M | 0.57% |
54EMBC | EMBECTA CORP | Healthcare | $364M | 0.54% |
55TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.52% |
56PEPG | PEPGEN INC | Healthcare | $349M | 0.52% |
57VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.52% |
58MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.49% |
59EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.49% |
60BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.47% |
61CV | CAPSOVISION INC | Healthcare | $314M | 0.47% |
62KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $311M | 0.47% |
63AGEN | AGENUS INC | Healthcare | $311M | 0.46% |
64TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.46% |
65EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.45% |
66EVMN | EVOMMUNE INC | Healthcare | $291M | 0.44% |
67OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.42% |
68CLPT | CLEARPOINT NEURO INC | Healthcare | $272M | 0.41% |
69QTTB | Q32 BIO INC | Healthcare | $264M | 0.39% |
70BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.39% |
71ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.36% |
72LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.36% |
73RXST | RXSIGHT INC | Healthcare | $226M | 0.34% |
74DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.34% |
75TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.30% |
76KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.30% |
77RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.29% |
78ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.28% |
79OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.25% |
80STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.24% |
81INGN | INOGEN INC | Healthcare | $146M | 0.22% |
82RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.19% |
83BDSX | BIODESIX INC | Healthcare | $109M | 0.16% |
84IMUX | IMMUNIC INC | Healthcare | $106M | 0.16% |
85CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.15% |
86ICCC | IMMUCELL CORP | Healthcare | $93M | 0.14% |
87JYNT | JOINT CORP | Healthcare | $92M | 0.14% |
88NRXS | NEURAXIS INC | Healthcare | $82M | 0.12% |
89ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.12% |
90NTRB | NUTRIBAND INC | Healthcare | $73M | 0.11% |
91XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.09% |
92POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.08% |
93COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.08% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $66.85B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 18% toward Large, 52% toward Growth. +40% unclassified (21 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T032403 rates=20261113T032429
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 1.87 (pass) but Gaussian VaR gives 2.07 (fail). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 18.6% | -1.6% |
| 3 yearsp.a. | 14.5% | -1.2% |
| 5 yearsp.a. | -1.5% | -10.5% |
| 10 yearsp.a. | 0.8% | -10.3% |
| Since inceptionp.a. | 5.5% | -3.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 13.5% | -7.6% |
| 2025 | 22.8% | 4.8% |
| 2024 | -10.1% | -13.6% |
| 2023 | 16.7% | 12.0% |
| 2022 | -33.1% | -30.0% |
| 2021 | -17.5% | -32.6% |
| 2020 | 36.4% | 16.4% |
| 2019 | 24.3% | 3.6% |
| 2018 | -20.2% | -22.1% |
| 2017 | 4.8% | -14.4% |
| 2016 | -15.6% | -6.8% |
| 2015 | 8.7% | 3.4% |
| 2014 | 21.3% | -3.7% |
| 2013 | 53.9% | 8.3% |
| 2012 | 27.5% | 9.3% |
| 2011 | -19.9% | -25.4% |
| 2010 | 2.7% | -0.6% |
| 2009 | 41.1% | 22.9% |
| 2008 | -32.4% | -8.7% |
| 2007 | -13.3% | -19.9% |
| 2006 | 2.8% | 0.2% |
| 2005 | -14.4% | -23.8% |
| 2004 | 10.5% | 1.4% |
| 2003 | 60.1% | 33.6% |
| 2002 | -40.8% | -19.9% |
| 2001 | 58.4% | 86.4% |
| 2000 | 36.2% | 1.1% |
| 1999 | 30.3% | 1.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Price Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Price signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.